Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safeguard failures in Canada's MAiD system.

BMJ supportive & palliative care·2026
Same author

Pharmaceutical governance system for costly drugs through human rights due diligence.

BMJ (Clinical research ed.)·2025
Same author

Canadian MAID Reform: Response to Peer Commentaries from Holland et al., Downar et al., Peters and Others.

The American journal of bioethics : AJOB·2025
Same author

Euthanasia as Medical Therapy in Canada.

The Hastings Center report·2025
Same author

Canadian Medical Assistance in Dying: Provider Concentration, Policy Capture, and Need for Reform.

The American journal of bioethics : AJOB·2025
Same author

When Death Becomes Therapy: Canada's Troubling Normalization of Health Care Provider Ending of Life.

The American journal of bioethics : AJOB·2023

Related Experiment Video

Updated: May 12, 2026

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

Pharmaceutical knowledge governance: a human rights perspective.

Trudo Lemmens1

  • 1University of Toronto.

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|April 16, 2013
PubMed
Summary

Industry control over pharmaceutical data presents a public health risk. A human rights analysis reveals how to improve drug regulation and ensure clinical trial transparency for better health outcomes.

Area of Science:

  • Public Health
  • Health Policy
  • Bioethics

Background:

  • Industry influence on pharmaceutical data raises public health and funding concerns.
  • Recent scandals involving flawed data in medical journals underscore the need for better pharmaceutical knowledge governance.
  • Existing drug regulations may inadvertently facilitate industry control over knowledge production.

Purpose of the Study:

  • To analyze pharmaceutical knowledge governance as a human rights concern.
  • To explore how human rights frameworks can promote independent knowledge governance.
  • To identify necessary reforms in drug regulation and global responses.

Main Methods:

  • Analysis of challenges in the current pharmaceutical knowledge deficit.
  • Review of case law to identify human rights interests.

Related Experiment Videos

Last Updated: May 12, 2026

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

  • Conceptual application of human rights as a methodology for analyzing contributing factors.
  • Examination of historical, economic, cultural, and social factors.

    • Main Results:

    • Industry control over pharmaceutical data poses significant public health risks.
    • Human rights principles can support state obligations for independent knowledge governance, including clinical trial transparency.
    • Historical drug regulations have contributed to industry control over pharmaceutical knowledge.
    • A comprehensive analysis reveals interwoven factors driving the problem.

    Conclusions:

    • Pharmaceutical knowledge governance is a critical human rights issue.
    • States have an obligation to ensure independent knowledge governance and clinical trial transparency.
    • Reforms in drug regulation informed by human rights analysis are essential.
    • A global, human rights-based approach is recommended for pharmaceutical knowledge governance.